DelveInsight's multiple sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for multiple sclerosis treatment. Key multiple sclerosis ...

Apogee Therapeutics, Inc. ( (APGE)) has released its Q3 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to its investors. Apogee Therapeutics, Inc. is a ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

Allspring Global Investments Holdings LLC lessened its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 6 ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...